Recipient: Park Yeonhee, Professor at Sungkyunkwan University School of Medicine

Recognized for Advancing Precision Medicine in Breast Cancer

Boreung and the Korea Cancer Research Foundation announced on the 19th that they held the 25th Boreung Cancer Academic Awards ceremony.


At the 25th Boryung Cancer Award ceremony held on the 19th at the Lee Geonhee Hall of Seoul National University Cancer Research Institute, Im Seoka, Chairman of the Korea Cancer Research Foundation (first from left), Park Yeonhee, Professor at Sungkyunkwan University School of Medicine (second from left), and Kim Eunseon, Chairperson of Boryung Holdings, are taking a commemorative photo after the ceremony. Boryung

At the 25th Boryung Cancer Award ceremony held on the 19th at the Lee Geonhee Hall of Seoul National University Cancer Research Institute, Im Seoka, Chairman of the Korea Cancer Research Foundation (first from left), Park Yeonhee, Professor at Sungkyunkwan University School of Medicine (second from left), and Kim Eunseon, Chairperson of Boryung Holdings, are taking a commemorative photo after the ceremony. Boryung

View original image

The award ceremony, held that day at Lee Geonhee Hall of the Seoul National University Cancer Research Institute, was attended by Park Yeonhee, Professor at Sungkyunkwan University School of Medicine and award recipient; Lim Jaejoon, Dean of Seoul National University College of Medicine; Lee Joonhaeng, Dean of Sungkyunkwan University School of Medicine; Im Seoka, Chairwoman of the Korea Cancer Research Foundation and members of the executive board; and Kim Eunseon, Chairwoman of Boreung Holdings. Previous recipients, including Park Jaegap, Chairman of the Korea Cell Line Research Foundation; Yang Hangwang, Director of the National Cancer Center; and Jung Seungyong, Professor at Seoul National University College of Medicine, also attended, adding significance to the event. During the ceremony, Professor Park Yeonhee received a prize of 30 million won and a plaque, and there was also a session for reporting academic achievements.


The Boreung Cancer Academic Award is a prize jointly established in 2002 by the Korea Cancer Research Foundation and Boreung to encourage and support researchers dedicated to cancer eradication for the improvement of public health. Having discovered innovative research achievements and contributed to the advancement of oncology research, this award has established itself as the most prestigious academic prize in the field of cancer research in Korea.


This year's recipient, Professor Park Yeonhee, has served as a professor of Hematology and Oncology at Sungkyunkwan University School of Medicine and Samsung Medical Center since 2008. For over 20 years, she has led changes in clinical practice and research in the field of breast cancer both in Korea and internationally.


In particular, the Young-PEARL study, which she led for premenopausal breast cancer patients, demonstrated the clinical efficacy of combining CDK4/6 inhibitors with endocrine therapy. This research has received high international recognition, such as the expansion of indications by the U.S. Food and Drug Administration (FDA). Additionally, her research integrating whole-genome analysis data and clinical information of breast cancer patients has proven her world-class research capabilities in the field of breast cancer precision medicine and contributed to actual improvements in patient care.


Im Seoka, Chairwoman of the Korea Cancer Research Foundation, stated, "Congratulations to Professor Park Yeonhee for leading clinical practice and innovative translational research in the field of breast cancer. We hope that today’s research achievements and academic challenges will lead to better treatments and hope for patients."



Kim Eunseon, Chairwoman of Boreung Holdings, said, "The Boreung Cancer Academic Award will continue to honor the dedication of researchers and support their ongoing research and challenges. Boreung will also do its utmost to improve cancer treatment conditions, including the stable supply of essential anticancer drugs, which are facing supply instability both domestically and abroad."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing